Systemic Sclerosis: Clinical Trials

13 trials for Systemic Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed. 13 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Completed 13
Phase 25Completed 5

Follow Systemic Sclerosis: new trials by email Literature Review of Systemic Sclerosis trials Research Report on Systemic Sclerosis

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of MK-2225 in Healthy Participants (MK-2225-003)
MK-2225, Placebo - Systemic Sclerosis
Phase 1CompletedMerck Sharp & Dohme LLC322023-11-212025-07-29
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis
RO7303509, Placebo - Systemic Sclerosis
Phase 1CompletedGenentech, Inc.562023-01-162025-07-20
A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
VIB7734, Placebo - Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Phase 1CompletedAmgen312018-12-132024-12-13
A Study of KHK4827 in Patients With Systemic Sclerosis
KHK4827 - Systemic Sclerosis
Phase 1CompletedKyowa Kirin Co., Ltd.82017-10-062025-07-11
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Tofacitinib, Placebo Oral Tablet - Systemic Sclerosis, Scleroderma
Phase 1 / Phase 2CompletedUniversity of Michigan152017-09-252020-05-08
Prevalence and Predictors of Proton Pump Inhibitor Partial Response in Gastroesophageal Reflux Disease in Systemic Sclerosis
Omeprazole 20mg - Systemic Sclerosis, Gastroesophageal Reflux
Phase 1CompletedKhon Kaen University2502013-05-012018-06-21
IL1-TRAP, Rilonacept, in Systemic Sclerosis
Rilonacept, Placebo - Scleroderma, Systemic Sclerosis
Phase 1 / Phase 2CompletedBoston University242011-12-012018-05-01
Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis
treprostinil diethanolamine - Systemic Sclerosis
Phase 1CompletedUnited Therapeutics282008-12-012012-10-23
A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis
Imatinib - Alveolitis, Systemic Sclerosis
Phase 1 / Phase 2CompletedUniversity of California, Los Angeles202007-08-012014-10-27
Rapamycin vs Methotrexate in Diffuse SSc
rapamycin, methotrexate - Systemic Sclerosis
Phase 1 / Phase 2CompletedUniversity of California, Los Angeles172002-08-012016-04-11
Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders
Stem Cell Transplantation, CD34 selection - Systemic Sclerosis, Systemic Lupus Erythematosus
Phase 1CompletedFred Hutchinson Cancer Center62000-11-012015-03-06
Stem Cell Transplant to Treat Patients With Systemic Sclerosis
Cyclophosphamide, Mesna, G-CSF - Systemic Sclerosis
Phase 1CompletedBaylor College of Medicine241999-06-012020-01-18
Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody - Systemic Sclerosis, Scleroderma
Phase 1 / Phase 2CompletedGenzyme, a Sanofi Company2015-03-05

Narrower conditions

Scleroderma, Systemic (13)  ·  Scleroderma, Diffuse (5)  ·  Dermatomyositis (2)  ·  Lupus Erythematosus, Systemic (2)  ·  Arthritis (1)  ·  Arthritis, Juvenile (1)  ·  Autoimmune Diseases (1)  ·  Communicable Diseases (1)  ·  Connective Tissue Diseases (1)  ·  Gastroesophageal Reflux (1)  ·  Immune System Diseases (1)  ·  Lupus Erythematosus, Cutaneous (1)  ·  Polymyositis (1)  ·  Rare Diseases (1)  ·  Sjogren's Syndrome (1)

Broader conditions

Skin Diseases (13)  ·  Skin and Connective Tissue Diseases (13)  ·  Connective Tissue Diseases (12)  ·  Joint Diseases (2)  ·  Muscular Diseases (2)  ·  Musculoskeletal Diseases (2)  ·  Myositis (2)  ·  Nervous System Diseases (2)  ·  Neuromuscular Diseases (2)  ·  Rheumatic Diseases (2)  ·  Arthritis (1)  ·  Arthritis, Rheumatoid (1)  ·  Autoimmune Diseases (1)  ·  Deglutition Disorders (1)  ·  Digestive System Diseases (1)

Interventions

Cyclophosphamide (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Imatinib Mesylate (1)  ·  Leukapheresis (1)  ·  Mesna (1)  ·  Methotrexate (1)  ·  Omeprazole (1)  ·  Sirolimus (1)  ·  Stem Cell Transplantation (1)  ·  Whole-Body Irradiation (1)  ·  brodalumab (1)  ·  rilonacept (1)  ·  tofacitinib (1)  ·  treprostinil (1)

Sponsors

University of California, Los Angeles (2)  ·  Amgen (1)  ·  Baylor College of Medicine (1)  ·  Boston University (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Genentech, Inc. (1)  ·  Genzyme, a Sanofi Company (1)  ·  Khon Kaen University (1)  ·  Kyowa Kirin Co., Ltd. (1)  ·  Merck Sharp & Dohme LLC (1)  ·  United Therapeutics (1)  ·  University of Michigan (1)

Countries

United States (11)  ·  Poland (2)  ·  Spain (2)  ·  Argentina (1)  ·  Belgium (1)  ·  France (1)  ·  Israel (1)  ·  Japan (1)  ·  Portugal (1)  ·  Puerto Rico (1)  ·  Serbia (1)  ·  United Kingdom (1)

Top investigators

Ann Woolfrey (1)  ·  Carol A. Wallace, MD (1)  ·  Daniel E. Furst, MD (1)  ·  Dinesh Khanna, MD (1)  ·  Kristan Rollins, PharmD (1)  ·  Philip J Clements, MD, MPH (1)  ·  Robert W Simms, MD (1)

Results publications

PMID 19950289, PMID 21769849, PMID 23597147, PMID 30277862, PMID 35943798, PMID 36997069

NIH funding

2018 (1)